GRAPE • Glycemic Response of Amylopectin Containing Drinks (GRAPE)

September 7, 2022 updated by: Arizona State University

Glycemic Response of Amylopectin Containing Drinks

To quantify the glycemic index of the SP energy-smart-based nutrition supplement and the SP Glucose-support formula as compared to a glucose drink. We hypothesized that both the energy-smart-based nutritional supplement and the SP Glucose-support formula will have low glycemic index.

The aim of the study is to quantify the glycemic index of the SP energy-smart-based nutrition supplement and the SP Glucose-support formula as compared to a glucose drink. We hypothesized that both the energy-smart-based nutritional supplement and the SP Glucose-support formula will have low glycemic index.

Study Overview

Detailed Description

Subjects: 9 non-diabetic (HbA1c < 6.5) males aged 30-55 years with body mass indices ranging from 27.5 to 35 kg∙m-2. Individuals with impaired glucose tolerance will be included as long as they are not diagnosed with diabetes and their HbA1c is less than 6.5.

Preliminary Testing: Medical history, weight, height, body composition via dual x-ray absorptiometry (DXA) and glycosylated hemoglobin (HbA1c) measurement.

Protocol: After a 10-hour overnight fast, subjects will complete 3 experimental visits in which they will ingest one of three beverages in a randomized order. During experimental visits subjects will either be given the following 3 experimental drinks:

  • Full SP-glucose balance formula (200 kcal)
  • Energy smart carbohydrate blend (50 g, 200 kcal)
  • Liquid dextrose solution in the form of TRUTOL ® Glucose Tolerance Test Beverage (50 g, 200 kcal)

Study Type

Interventional

Enrollment (Actual)

15

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Arizona
      • Phoenix, Arizona, United States, 85004
        • Arizona Biomedical Collaborative

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

30 years to 55 years (Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

Male

Description

Inclusion Criteria:

  • BMI 27.5 to 35 kg∙m-2

Exclusion Criteria:

  • Diagnosed diabetes
  • HbA1c > 6.5
  • competitive athletes
  • body weigh change > 3kg during last month

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Standard Process - glucose balance
Standard Process - glucose balance formula (200 kcal)
Meal replacement drink containing 200 kcal
Other Names:
  • SP-glucose balance formula
Experimental: Energy smart Carbohydrate blend
Energy smart carbohydrate blend (50 grams, 200 kcal)
Carbohydrate blend drink designed for low glycemic responses containing 200 kcal
Active Comparator: Liquid Dextrose Control
Liquid dextrose solution in the form of TRUTOL ® Glucose Tolerance Test Beverage (50 grams, 200 kcal)
Liquid Dextrose drink of 200 kcal

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Area Under the Curve of Glucose
Time Frame: 120 minutes
Positive integer of the area under the Curve of glucose
120 minutes
Area Under the Curve for Insulin
Time Frame: 120 minutes
Positive integer of the area under the Curve of insulin
120 minutes
Blood glucose
Time Frame: 30, 60 and 120 minutes of the glucose challenge
Blood glucose levels
30, 60 and 120 minutes of the glucose challenge
Blood insulin
Time Frame: 30, 60 and 120 minutes of the glucose challenge
Blood insulin levels
30, 60 and 120 minutes of the glucose challenge

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
c-peptide
Time Frame: 30, 60, and 120 minutes of the glucose challenge
Blood levels of c-peptide
30, 60, and 120 minutes of the glucose challenge
glucagon
Time Frame: 30, 60, and 120 minutes of of the glucose challenge
Blood levels of glucagon
30, 60, and 120 minutes of of the glucose challenge
Leptin
Time Frame: 30, 60, and 120 minutes of the glucose challenge
Blood levels of leptin
30, 60, and 120 minutes of the glucose challenge
Adiponectin
Time Frame: 30, 60, and 120 minutes of the glucose challenge
Blood levels of adiponectin
30, 60, and 120 minutes of the glucose challenge
glucagon-like-peptide-1
Time Frame: 30, 60, and 120 minutes of the glucose challenge
Blood levels of glucagon-like-peptide-1
30, 60, and 120 minutes of the glucose challenge

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Collaborators

Investigators

  • Principal Investigator: Stavros Kavouras, PhD, Arizona State University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 23, 2019

Primary Completion (Actual)

August 30, 2021

Study Completion (Actual)

August 30, 2021

Study Registration Dates

First Submitted

April 12, 2019

First Submitted That Met QC Criteria

April 12, 2019

First Posted (Actual)

April 16, 2019

Study Record Updates

Last Update Posted (Actual)

September 8, 2022

Last Update Submitted That Met QC Criteria

September 7, 2022

Last Verified

September 1, 2022

More Information

Terms related to this study

Other Study ID Numbers

  • FP00016578

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Glycemic Index

Clinical Trials on Carbohydrate drink

3
Subscribe